Lifeboat Foundation

Deloitte’s Global Generative AI Innovation Leader Nitin Mittal and Tomorrow CEO Mike Walsh explore the Fifth Industrial Revolution in which the catalyst for societal transformation is the augmentation and expansion of human intelligence.

Given the recency of the Fourth Industrial Revolution, it might be a surprise that we are on the verge of an entirely new one. Rapid progress in computation, connectivity, and artificial intelligence (AI)—accelerated by the COVID-19 pandemic—has brought forward the timeline for transformation. While prior industrial revolutions were premised on gains in operational efficiency, the next revolution will be powered by minds, not just machines—where the catalyst for societal transformation is the augmentation and expansion of human intelligence.

The US is dealing with an “out-of-control” epidemic of sexually transmitted infections, according to the National Coalition of STD Directors.

The warning comes after the release of an annual data report on STIs by the US Centers for Disease Control and Prevention (CDC).

The exasperation of public health officials can be felt in the very first sentence of the online announcement.

With transformer #AI protein #design and major advances in #DNA #synthesis, how do we deal with #biosecurity concerns?

The organoids are the size of grain of sand and a special robot is used to screen which treatment kills off the tumour more effectively.

It helps take the guesswork out of treating advanced bowel cancer which can be difficult to beat.

“Each time you give a patient an ineffective treatment, you lose two to three months on something that won’t work,” Gibbs said.

Adding toripalimab (Loqtorzi) to chemo extended survival in people with nasopharyngeal cancer that returned after initial treatment or spread in the body.

Rates of kidney stones are on the rise in the United States and around the world. Type 2 diabetes is associated with increased risk of kidney stones, but some forms of treatment for this condition may also have the benefit of lowering risk of kidney stones.

In a study led by investigators from Mass General Brigham, researchers found that there was an association between the use of sodium-glucose contratransporter 2 (SGLT2) inhibitors and a lower risk of developing kidney stones. Their findings are reported in JAMA Internal Medicine.

Researchers from Brigham and Women’s Hospital and Massachusetts General Hospital worked together to conduct the analysis. The study included data from three nationwide databases of patients with type 2 diabetes who were seen in routine clinical practice. The team analyzed information from 716,406 adults with type 2 diabetes who had started taking an SGLT2 inhibitor or two other classes of diabetes medications known as GLP1 receptor agonists or dipeptidyl peptidase 4 (DPP4) inhibitors.

Scientists discovered “obelisks” described as a new biological “entity” in the human body. “It’s insane,” one researcher told Science Magazine.

Abstract. Important progress has been made over the last decade in the classification, imaging, and treatment of neuroendocrine neoplasm (NENs), with several new agents approved for use. Although the treatment options available for patients with well-differentiated neuroendocrine tumors (NETs) have greatly expanded, the rapidly changing landscape has presented several unanswered questions about how best to optimize, sequence, and individualize therapy. Perhaps the most important development over the last decade has been the approval of ¹⁷⁷ Lu-DOTATATE for treatment of gastroenteropancreatic-NETs, raising questions around optimal sequencing of peptide receptor radionuclide therapy (PRRT) relative to other therapeutic options, the role of re-treatment with PRRT, and whether PRRT can be further optimized through use of dosimetry among other approaches. The NET Task Force of the National Cancer Institute GI Steering Committee convened a clinical trial planning meeting in 2021 with multidisciplinary experts from academia, the federal government, industry, and patient advocates to develop NET clinical trials in the era of PRRT. Key clinical trial recommendations for development included 1) PRRT re-treatment, 2) PRRT and immunotherapy combinations, 3) PRRT and DNA damage repair inhibitor combinations, 4) treatment for liver-dominant disease, 5) treatment for PRRT-resistant disease, and 6) dosimetry-modified PRRT.

How Obesity Dismantles the Powerhouse of the Cell: A new UC San Diego School of Medicine study in Nature Portfolio (Metabolism) sheds light on how obesity affects our mitochondria, the all-important energy-producing structures of our cells.

UC San Diego researchers found that when mice were fed a high-fat diet, mitochondria within their fat cells broke apart and were less able to burn fat, leading to weight gain. They also found they could reverse the effect by targeting a single gene, suggesting a new treatment strategy for obesity.